Epicatechin.
A closer look at
blood flow & muscle.

Methods: Water-based (-)-epicatechin was compared with water alone in four treatment conditions. Investigators measured brachial-artery FMD, forearm laser-Doppler responses, peripheral blood pressure and circulating metabolites at baseline and 1, 2, 4 and 6 hours.

Results: FMD increased significantly at 1 and 2 hours after 1.0 mg/kg and at 2 hours after 0.5 mg/kg. There were no significant changes in laser-Doppler measurements or blood pressure at any dose or time, and circulating nitrite/nitrate changes were nonsignificant.

Limits: Small, male-only acute study. The accessed primary abstract does not supply FMD effect sizes, confidence intervals or washout details. It does not establish sustained blood-pressure lowering or fewer cardiovascular events.

[1] Open the publication in the source list.

Methods: Apparently healthy adults with screening systolic blood pressure of 125–160 mmHg received pure (-)-epicatechin, quercetin-3-glucoside (160 mg/day) and placebo capsules in random order. Quercetin was a separate condition, not a co-ingredient. The primary endpoint was pre-to-post change in FMD.

Results versus placebo: FMD +1.1 percentage points (95% CI −0.1 to 2.3; p=0.07). Fasting insulin −1.46 mU/L (95% CI −2.74 to −0.18; p=0.03). HOMA-IR, a calculated insulin-resistance index, −0.38 (95% CI −0.74 to −0.01; p=0.04). No effect on fasting glucose, office or 24-hour blood pressure, arterial stiffness, nitric oxide, endothelin-1 or lipid profile.

Limits: Primary-abstract verification. A small trial with multiple secondary outcomes and no long-term clinical endpoints. A confidence interval crossing zero means the FMD estimate is compatible with no effect.

[2] Open the publication in the source list.

Methods: Pure epicatechin capsules, with grip dynamometry and blood sampling before and after treatment. Participants made three attempts per hand, alternating hands; maximum strength was analyzed. The paper separately studied mice and banked human muscle biopsies. Those are not additional supplemented participants.

Results: The authors reported an approximately 7% bilateral grip-strength increase and a 49.2 ± 16.6% rise in the plasma follistatin/myostatin ratio. The ratio is a blood marker, not a percentage of new muscle. Muscle growth was not established in the human intervention.

Limits: Only six people, no placebo or blinding described, and one week of follow-up. Repeated-test familiarity, normal variability and other influences cannot be separated from a treatment effect. The methods specify 25 mg twice daily but also give an approximate weight-based description that does not align cleanly with the reported mean weight; the explicit capsule regimen is reported here.

[3] Open the publication in the source list.

Population and methods: Korean adults aged at least 60, mean 64.1 among those analyzed; 57 of 67 were women. Low gait speed and low grip strength were exclusion criteria, so this was not a treatment trial in established sarcopenia. Forty participants were assigned to each group, with no added exercise program. Knee torque, dynamometer grip, DXA muscle mass and blood markers were measured.

Formula: Tannase-treated Camellia sinensis extract in twice-daily capsules, compared with microcrystalline cellulose placebo. The extract contained 101.35 mg epicatechin per gram and 201.36 mg gallic acid per gram. At 600 mg extract/day, this corresponds to approximately 60.81 mg epicatechin and 120.82 mg gallic acid/day, calculated from the reported concentrations. It was not 600 mg pure epicatechin.

Results: Right-knee flexor peak-torque change +6.18 versus −1.85 N·m (p=0.013). Right-grip change −0.15 versus −1.57 kg (p=0.037). No significant between-group change in total or regional muscle mass. Myostatin change favored extract (p=0.045); follistatin did not (p=0.566).

Limits: Four withdrawals, four protocol exclusions and five further exclusions based on initial muscle indices/hormone levels left 33 extract and 34 placebo participants. This was not a full intention-to-treat analysis. Multiple comparisons, baseline knee-strength differences and the multicomponent formula limit interpretation. Tables are used here rather than the abstract’s broader muscle-growth language.

[4] Open the publication in the source list.

Methods: Recreationally active men and women ages 18–30 completed four cycle sessions weekly, combining steady and high-intensity work. The preparation was described as 98% pure (-)-epicatechin; placebo was cellulose. Testing included oxygen uptake, a Wingate anaerobic test, blood and muscle biopsies. Supplements were stopped 24 hours before post-testing.

Sample: Twenty of 29 participants completed the study. Relative peak-oxygen data were available for nine per group; blood and muscle samples were available for 16 completers. Missing exercise tests included a placebo-group fainting episode and an equipment malfunction.

Results: Relative peak oxygen uptake showed a group-by-time interaction (p=0.04), favoring placebo’s training response. The muscle mitochondrial protein succinate dehydrogenase increased in placebo but not epicatechin (interaction p=0.02). Myostatin gene expression was not significantly changed. Anaerobic adaptations had no supplement advantage.

Limits: Small sample, attrition and four-week follow-up. Circulating epicatechin was not measured, and no endurance time trial was performed. These results argue against assuming a training benefit, not for a universal harm claim across all doses and exercise types.

[5] Open the publication in the source list.

Methods: Healthy adults received purified powder dissolved in water. Three people per group took a single 50, 100 or 200 mg dose. In the repeated-dose study, four per group received 50 mg once or twice daily for five days. Serial blood sampling was performed through six hours, repeated on day 5 for the multiple-dose groups.

Results: Rapid absorption and extensive phase II metabolism were observed. Day-5 follistatin exposure over the sampling period was approximately 2.5 times day 1 in the twice-daily group. Nitrite and platelet mitochondrial-enzyme measures also changed. These are exploratory biomarkers in tiny uncontrolled groups, not muscle biopsy or hypertrophy results.

Safety and limits: No attributable adverse effects were reported or observed. Platelet-count and alkaline-phosphatase changes remained within normal ranges but warranted monitoring in longer studies. No formal power calculation or placebo control. Five-day tolerability at these amounts does not establish safety of a 1,000 mg daily regimen.

[6] Open the publication in the source list.

Methods: The review followed PRISMA 2020 and used the Cochrane RoB 2 tool to assess bias. It searched PubMed and Web of Science through July 1, 2022, and selected trials designed to isolate epicatechin’s contribution; co-ingredients were allowed when also present in the control condition. Seven trials examined a bolus dose, three regular intake, and one acute-on-chronic intake. Single-dose exposures included 0.1–2.0 mg/kg or 100–200 mg; repeated exposures were 25 or 100 mg/day for two or four weeks. Outcomes included vascular function, glucose and lipid metabolism, oxidative stress, inflammation, appetite and body weight.

Results: Dose-related acute improvements in FMD and peripheral arterial tonometry were observed in healthy young adults. Beyond these acute vascular measures, consistent benefits were not established. Individual secondary signals, such as the insulin findings above, need to be read against this broader pattern.

Limits: Most trials had some risk-of-bias concerns. Small studies and secondary endpoints leave uncertainty about whether null results reflect no effect or insufficient power. This review concerns cardiometabolic outcomes, not proof for muscle growth. Its 11 trials overlap some studies on this page and should not be added to them as independent evidence.

[7] Open the publication in the source list.